Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring

被引：0
|
作者：
Gonczi, L. [1 ]
Ilias, A. [1 ]
Szanto, K. [2 ]
Kurti, Z. [1 ]
Golovics, P. A. [3 ]
Farkas, K. [2 ]
Schafer, E. [3 ]
Szepes, Z. [2 ]
Szalay, B. [4 ]
Vincze, A. [5 ]
Szamosi, T. [3 ]
Molnar, T. [2 ]
Lakatos, P. [6 ]
机构：
[1] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[2] Univ Szeged, Dept Med 1, Szeged, Hungary
[3] Mil Hosp, State Hlth Ctr, Dept Gastroenterol, Budapest, Hungary
[4] Semmelweis Univ, Dept Lab Med, Budapest, Hungary
[5] Univ Pecs, Dept Med 1, Pecs, Hungary
[6] McGill Univ, Div Gastroenterol, Hlth Ctr, Montreal, PQ, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.533
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P409
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [1] NON-MEDICAL REVERSE SWITCH BETWEEN THE ORIGINATOR INFLIXIMAB AND ITS BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: CLINICAL OUTCOMES AND THERAPEUTIC DRUG MONITORING
    Gonczi, Lorant
    Ilias, Akos
    Szanto, Kata
    Kurti, Zsuzsanna
    Golovics, Petra Anna
    Farkas, Klaudia
    Schafer, Eszter
    Szepes, Zoltan
    Szalay, Balazs
    Vincze, Aron
    Szamosi, Tamas
    Molnar, Tamas
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2019, 156 (06) : S876 - S877
  • [2] Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease
    Haghnejad, Vincent
    Le Berre, Catherine
    Dominique, Yoann
    Zallot, Camille
    Guillemin, Francis
    Peyrin-Biroulet, Laurent
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (03) : 281 - 288
  • [3] The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
    Dutt, Krishneel
    Srinivasan, Ashish
    Van Langenberg, Daniel
    BIODRUGS, 2022, 36 (05) : 639 - 644
  • [4] The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
    Krishneel Dutt
    Ashish Srinivasan
    Daniel Van Langenberg
    BioDrugs, 2022, 36 : 639 - 644
  • [5] The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
    Ranjan, R.
    Myers, S.
    Crissop, L.
    Ritchie, S.
    Maw, F.
    Sebastian, S.
    Dhar, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S335 - S335
  • [6] THE IMPACT OF THERAPEUTIC DRUG MONITORING DURING BIOSIMILAR INFLIXIMAB SWITCH IN INFLAMMATORY BOWEL DISEASE
    Ranjan, Ravi
    Myers, Sally
    Crissop, Linda
    Ritchie, Susan
    Maw, Frances
    Sebastian, Shaji
    Dhar, Anjan
    GUT, 2018, 67 : A74 - A74
  • [7] Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study
    Lontai, Livia
    Gonczi, Lorant
    Balogh, Fruzsina
    Komlodi, Nora
    Resal, Tamas
    Farkas, Klaudia
    Molnar, Tamas
    Miheller, Pal
    Golovics, Petra A.
    Schafer, Eszter
    Szamosi, Tamas
    Ilias, Akos
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (12) : 1639 - 1645
  • [8] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
  • [9] A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months' Clinical Outcomes from the Danbio Registry
    Glintborg, Bente
    Sorensen, Inge Juul
    Jensen, Dorte Vendelbo
    Krogh, Niels Steen
    Loft, Anne Gitte
    Espesen, Jakob
    Olsen, Jimmi
    Hendricks, Oliver
    Grydehoj, Jolanta
    Hansen, Inger Marie Jensen
    Sorensen, Michael Veedfald
    Chrysidis, Stavros
    Andersen, Birgitte Lange
    Manilo, Natalia
    Klarlund, Mette
    Andersen, Lis Smedegaard
    Nordin, Henrik
    Kristensen, Salome
    Norregaard, Jesper
    Hetland, Merete Lund
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] NON-MEDICAL MANDATORY REVERSED AND BACK AND FORTH SWITCH BETWEEN INFLIXIMAB AND ITS BIOSIMILAR: EARLY CLINICAL OUTCOMES
    Ilias, Akos
    Szanto, Kata
    Gonczi, Lorant
    Kurti, Zsuzsanna
    Golovics, Petra Anna
    Szamosi, Tamas
    Schafer, Eszter
    Farkas, Klaudia
    Szepes, Zoltan
    Molnar, Tamas
    Vincze, Aron
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2018, 154 (06) : S822 - S822
12345